Clinical Trials | January 08, 2026
Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
India’s traditional medicine systems have also earned formal recognition in key bilateral trade agreements
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Subscribe To Our Newsletter & Stay Updated
